News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Projectile struck a vessel in the Strait of Hormuz, raising fears of disruptions to global energy flows and fuel-market volatility.
  • Palantir's Nebius partnership positions it as the software layer for sovereign AI, creating a direct government-contract demand pathway.
  • Keurig Dr Pepper pitched as a tactical buy on steady free cash flow, about 3% yield, and JDE Peet's integration upside.
  • Murphy Oil's execution and asset moves shifted the thesis toward predictable free cash flow and a medium-risk long trade.
  • Energy-route risk from the Strait incident likely lifts oil prices.

Latest Articles

Death of Bologna Businessman Puts Human Face on Europe’s Migration Row

Death of Bologna Businessman Puts Human Face on Europe’s Migration Row

The death of 42-year-old Moroccan-born metalworker Abderrahim Fakir after being restrained by police in Bologna has intensified Italy’s migrant debate. While political leaders used the incident to advance competing narratives, interviews with family, lawyers and friends depict a man contending with business troubles, anxiety over his residency and …

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nurix Therapeutics has enrolled the first patient in its pivotal Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg, a novel BTK degrader, against standard non-covalent BTK inhibitor pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The trial aims to demonstrate bexobrutideg’s superi…

Wix Reports Second Quarter 2026 Results

Wix Reports Second Quarter 2026 Results

Wix.com Ltd. announced robust second quarter 2026 financial results, with revenues increasing 15% year-over-year to $563 million, fueled by strong performance in its Base44 app-creation platform and continued growth in its core Wix business. The company launched Base44’s proprietary large language model (LLM) 'Base 1' to reduce AI operational costs…

IQM Quantum Computers Reports First Earnings as Public Company, Reporting First Half and Second Quarter 2026 Results, and Initiates FY 2026 Guidance Supported by Over EUR 102 million Order Backlog

IQM Quantum Computers Reports First Earnings as Public Company, Reporting First Half and Second Quarter 2026 Results, and Initiates FY 2026 Guidance Supported by Over EUR 102 million Order Backlog

IQM Quantum Computers Plc, a Finnish-based global leader in superconducting quantum computers, announced its first earnings as a public company for H1 and Q2 2026. The company reported EUR 8.9 million in revenues and an operating loss of EUR 60.5 million, supported by a substantial cash balance of EUR 309.4 million post listing. IQM expanded its ma…

WuXi AppTec Shares Jump After Strong H1 2026 Results and Raised Guidance

WuXi AppTec Shares Jump After Strong H1 2026 Results and Raised Guidance

WuXi AppTec's stock climbed sharply after the company reported first-half 2026 revenue of RMB 28.9 billion and net profit attributable to shareholders of RMB 11.08 billion, both well ahead of market expectations. Adjusted non-IFRS net profit rose markedly, the company raised full-year revenue guidance, and declared an interim cash dividend payable …

WuXi AppTec Shares Surge to Nearly Five-Year Peak After Strong H1 Results

WuXi AppTec Shares Surge to Nearly Five-Year Peak After Strong H1 Results

WuXi AppTec's H shares climbed more than 10% in Hong Kong to trade at their highest level since September 30, 2021, following first-half results that beat expectations. The Chinese contract research and manufacturing services firm reported a 33.7% rise in net profit attributable and a near 39% increase in revenue, driven by broad-based demand inclu…

India to Table Tax Bills to Attract Foreign Capital and Bolster Manufacturing

India to Table Tax Bills to Attract Foreign Capital and Bolster Manufacturing

The Indian government intends to seek parliamentary approval for a package of tax measures designed to draw foreign investment and reinforce domestic manufacturing capacity. Proposed legislation would formalize tax exemptions for foreign buyers of Indian government bonds, protect offshore funds from tax where management is India-based, and extend t…

Guggenheim Names Celldex Its Top Biotech Pick Ahead of Fall Phase III Data

Guggenheim Names Celldex Its Top Biotech Pick Ahead of Fall Phase III Data

Guggenheim Securities has designated Celldex Therapeutics as its leading biotechnology selection, highlighting the commercial promise of the company’s lead candidate, barzolvolimab, in the chronic urticaria market. Analysts kept a Buy rating and a $100 price target while pointing to approaching Phase III topline readouts and additional clinical upd…

Gotham City Research Accuses Sumitomo Pharma of Inflating FY2025 Revenue

Gotham City Research Accuses Sumitomo Pharma of Inflating FY2025 Revenue

Short seller Gotham City Research alleges Sumitomo Pharmaceutical misstated parts of its fiscal 2025 accounts by up to 165 billion yen, highlighting conflicting disclosures about a dividend from its Swiss subsidiary and claiming receivables were manipulated to boost profits. The report coincided with a 3.5%-4% drop in Sumitomo Pharma and Sumitomo C…

SK Hynix and Union Resume Talks Over Generous Bonus Plan at Cheongju Plant

SK Hynix and Union Resume Talks Over Generous Bonus Plan at Cheongju Plant

SK Hynix and representatives from one of its South Korean unions met for a fifth session of negotiations at the chipmaker’s Cheongju manufacturing complex to discuss a lucrative bonus scheme tied to annual operating profit. The company has proposed paying a large portion of bonuses in stock with restricted sale periods and introducing adjustments i…

Japan Airlines Shares Fall After Sharp Slide in Quarterly Operating Profit

Japan Airlines Shares Fall After Sharp Slide in Quarterly Operating Profit

Japan Airlines shares fell after the carrier reported a 72% year-on-year decline in operating profit for the April–June 2026 quarter, with results coming ¥12.0 billion under its guidance. Rising operating expenses, driven by elevated jet fuel prices linked to heightened Middle East geopolitical tensions, squeezed margins even as international passe…

Lumentum: Betting on the Optical Engine of AI — A 90% Upside Trade

Lumentum: Betting on the Optical Engine of AI — A 90% Upside Trade

Lumentum (LITE) sits at the center of the AI infrastructure supply chain. Recent headlines tying the company to Nvidia investments and multibillion-dollar purchase commitments, plus strong tape action and high short interest, set up an asymmetric trade: enter at $760, stop at $608, target $1,444 over a long-term (180 trading days) horizon. This is …

AI 3D Startup Vast Mulls Hong Kong IPO as Backers and Advisors Are Engaged

AI 3D Startup Vast Mulls Hong Kong IPO as Backers and Advisors Are Engaged

Vast, a Chinese artificial intelligence company focused on text- and image-driven 3D model generation, is weighing an initial public offering in Hong Kong. The company is reported to be working with global and domestic banks on a potential share sale, though discussions are ongoing and no final decision has been reached. Vast counts major technolog…

Schrödinger (SDGR): Buy a Software-Led AI Play Before the Re-rating

Schrödinger (SDGR): Buy a Software-Led AI Play Before the Re-rating

Schrdinger blends commercial simulation software with an in-house drug discovery pipeline. At roughly $1.14B market cap and an EV/Sales of ~3.4x on 2025 revenue of ~$256M, the company looks underpriced for a software-led growth story in the emerging AI drug discovery market. This trade idea outlines an actionable long with entry, stop and target c…

Mercedes-Benz: Buy the Post-Launch Recovery, Fade the Peak Costs

Mercedes-Benz: Buy the Post-Launch Recovery, Fade the Peak Costs

Mercedes-Benz Group AG shares are trading above key moving averages while technical momentum and a high-but-declining short interest profile set up a mid-term swing. The market is focused on elevated launch costs for new models that are masking an improving earnings trajectory. This trade idea uses a disciplined entry, stop and target and assumes c…

Australian Labor Market Maintains Hiring Momentum as Job Ads Climb in July

Australian Labor Market Maintains Hiring Momentum as Job Ads Climb in July

July advertising data from ANZ-Indeed indicates a 0.8 percent monthly increase in job postings, counterbalancing June's minor decline. The labor market continues to show resilience amid the Reserve Bank of Australia's rate hikes, with management and healthcare roles leading occupational expansion while unemployment remains steady.

Buy Constellation Energy (CEG): Own the Grid’s Clean Baseload Play

Buy Constellation Energy (CEG): Own the Grid’s Clean Baseload Play

Constellation Energy controls roughly 22 GW of operating nuclear capacity, has marquee hyperscaler contracts and a clean utility profile. At $274.49 and a market cap near $98.5B, the stock trades at mid-teens EV/EBITDA and a P/E under 25, leaving room for re-rating as nuclear demand accelerates. I rate CEG a Strong Buy with an entry at $274.49, sto…